These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38011614)

  • 21. The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission.
    Ido K; Nakamae M; Koh H; Okamura H; Nanno S; Nishimoto M; Takeoka Y; Hirose A; Nakashima Y; Hashimoto Y; Nakane T; Hino M; Nakamae H
    Transplantation; 2019 Oct; 103(10):2201-2210. PubMed ID: 30801534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
    Uzunel M; Ringdén O
    Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
    Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.
    Salit RB; Deeg HJ
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1023-35. PubMed ID: 25459177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
    Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.
    Di Grazia C; Pozzi S; Geroldi S; Grasso R; Miglino M; Colombo N; Tedone E; Luchetti S; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Galaverna F; Ghiso A; Sica S; Bacigalupo A
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1242-1246. PubMed ID: 26970379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.
    Tyler EM; Jungbluth AA; O'Reilly RJ; Koehne G
    Blood; 2013 Jan; 121(2):308-17. PubMed ID: 23160468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
    Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review.
    Konishi Y; Kondo T; Nakao K; Asagoe K; Otsuka Y; Nishikori M; Hishizawa M; Yamashita K; Takaori-Kondo A
    Bone Marrow Transplant; 2019 Feb; 54(2):326-329. PubMed ID: 30087462
    [No Abstract]   [Full Text] [Related]  

  • 32. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis.
    Válková V; Polák J; Marková M; Vítek A; Hájková H; Sálek C; Procházka B; Cetkovský P; Trněný M
    Clin Transplant; 2013; 27(1):E21-9. PubMed ID: 23231003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms.
    Haslam K; Molloy KM; Conneally E; Langabeer SE
    Clin Chem Lab Med; 2014 Mar; 52(3):e29-31. PubMed ID: 24423581
    [No Abstract]   [Full Text] [Related]  

  • 34. Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion.
    Dolan M; Cioc A; Cross NC; Neglia JP; Tolar J
    Pediatr Blood Cancer; 2012 Jul; 59(1):194-6. PubMed ID: 22106025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation.
    Liu H; Wang X; Zhang H; Wang J; Chen Y; Ma T; Shi J; Kang Y; Xi J; Wang M; Zhang M
    Mol Med Rep; 2019 Sep; 20(3):2426-2432. PubMed ID: 31257540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerated and Blast Phase Myeloproliferative Neoplasms.
    Jain T; Rampal RK
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):325-335. PubMed ID: 33641872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes.
    Wayne AS; Barrett AJ
    Hematol Oncol Clin North Am; 2003 Oct; 17(5):1243-60. PubMed ID: 14560785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
    Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
    Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism.
    Woehlecke C; Wittig S; Sanft J; Kreyenberg H; Gruhn B
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1283-90. PubMed ID: 25617314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant.
    Sperotto A; Gottardi M; Candoni A; Toffoletti E; De Marchi R; Petruzzellis G; Pizzano U; Fanin R
    Leuk Res; 2021 Sep; 108():106587. PubMed ID: 34020318
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.